Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Cash from Financing Activities (2020 - 2026)

Treace Medical Concepts filings provide 6 years of Cash from Financing Activities readings, the most recent being $1.4 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 5215.38% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 1198.12% increase, with the full-year FY2025 number at $2.1 million, up 1198.12% from a year prior.
  • Cash from Financing Activities hit $1.4 million in Q4 2025 for Treace Medical Concepts, up from -$10000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $107.9 million in Q1 2023 to a low of -$1.2 million in Q1 2021.
  • Median Cash from Financing Activities over the past 5 years was $304000.0 (2022), compared with a mean of $12.0 million.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 3793.94% in 2021 and later surged 7762.9% in 2023.
  • Treace Medical Concepts' Cash from Financing Activities stood at $1.0 million in 2021, then tumbled by 71.05% to $297000.0 in 2022, then plummeted by 44.44% to $165000.0 in 2023, then tumbled by 84.24% to $26000.0 in 2024, then skyrocketed by 5215.38% to $1.4 million in 2025.
  • The last three reported values for Cash from Financing Activities were $1.4 million (Q4 2025), -$10000.0 (Q3 2025), and $987000.0 (Q2 2025) per Business Quant data.